Mycobacterium Citations List: April 2025

Literature Citations

1. Design, Synthesis, Antioxidant, Antitubercular Activity, and In Silico Studies of Novel Α-amino Phosphonates of Vanillin, a Potent Bioactive Molecule. Aasif, M. and J.A. Banday. Russian Journal of Bioorganic Chemistry, 2025. 51(2): p. 629-641. ISI[001460792600030].
[WOS]. TB_04_2025.

2. Design, Synthesis and Biological Evaluation of Ethyl 5-(1-benzyl-1H-indol-5-yl) isoxazole-3-carboxylates as Antimycobacterial Agents. Bandela, R., S.K. Sahoo, A. Mukhopadhyay, M. Imran, A. Singampalli, S. Maddipatla, S.M. Bellapukonda, D. Panchal, S. Nanduri, A. Dasgupta, S. Chopra, and V.M. Yaddanapudi. ChemMedChem, 2025. 20(7): e202400902. PMID[39734278].
[PubMed]. TB_04_2025.

3. 6-phenoxyl-4-aminoquinoline: Synthesis and Preliminary Antitubercular-structure Activity Relationship Analyses. Beteck, R.M., L.J. Legoabe, P.S. Dube, A. Jordaan, and D.F. Warner. Medicinal Chemistry Research, 2025. ISI[001459431500001].
[WOS]. TB_04_2025.

4. Synthesis, Antituberculosis Evaluation and Structure-activity Relationships of New SQ109 Analogs. Dos Reis, D.B., E.P.M. Linhares, E.S.G. Dos Santos, F.H. do Carmo Ferreira, L.A.S. Costa, E.P. Ávila, M.V. de Almeida, M.V.N. de Souza, M.C. da Silva Lourenço, and M.F. Saraiva. Archiv der Pharmazie, 2025. 358(4): e3130. PMID[40235339].
[PubMed]. TB_04_2025.

5. Synergistic Anti-inflammatory and Anti-Tb Effects of Au-Pt-Cu Nanofluids: Experimental and Computational Insights. Dubey, A., M. Kumar, A.M. Alanazi, A. Tufail, and A.D. Bagul. Future Medicinal Chemistry, 2025. 17(6): p. 641-658. PMID[40114595]. PMCID[PMC11938965].
[PubMed]. TB_04_2025.

6. Exploring Antitubercular Activity of New Coumarin Derivatives Targeting Enoyl Acyl Carrier Protein Reductase (InhA): Synthesis, Biological Evaluation and Computational Studies. Ebaid, M.S., M. Korycka-Machala, M.A. Shaldam, M.G. Thabit, M. Kawka, B. Dziadek, M. Kuziola, H.A.A. Ibrahim, X.S. Lei, A.I. Elshamy, J. Dziadek, and A. Sabt. Journal of Molecular Structure, 2025. 1336: 142074. ISI[001455319800001].
[WOS]. TB_04_2025.

7. Synthesis and Antimicrobial Evaluation of Hybrids Methoxynaphthalene-N-acylhydrazones/1,3,4-oxadiazoles. Frederico Rozada, A.M., C. Maçon, J.L.A. Santos, R.M. Ferreira, M.L.F. da Motta Dacome, R.P. Mendes, F.A. Vicente Seixas, K. Caleffi, E.A. Basso, and G. de Freitas Gauze Bandoch. Future Medicinal Chemistry, 2025. 17(8): p. 885-898. PMID[40265271].
[PubMed]. TB_04_2025.

8. Design, Synthesis, and Anti-mycobacterial Evaluation of Triclosan-isoniazid Hybrids. Gupta, N., S. Chowdhary, F. Roquet-Baneres, L. Kremer, and V. Kumar. Chemistry & Biodiversity, 2025. 22(4): e202401967. PMID[39539099].
[PubMed]. TB_04_2025.

9. Essential Oils and Their Active Constituents Effective against Non-growing Mycobacterium Intracellulare. Jiang, X., D. Cao, B. Xu, X. Yuan, Y. Xiang, T. Wu, and Y. Zhang. BMC Complementary Medicine and Therapies, 2025. 25(1): 122. PMID[40165207]. PMCID[PMC11956417].
[PubMed]. TB_04_2025.

10. Discovery of Ultra Short Β-peptoids with Selective Activity against Drug-resistant Mycobacterium tuberculosis. Kauffman, J., J. Cuevas, J. Feiner, M. Metzger, G. Shetye, B. Wan, M. Qader, D. Nguyen, A. Nugent, A. Hossain, S. Franzblau, and F.E. Umesiri. European Journal of Medicinal Chemistry, 2025. 290: 117531. PMID[40147341].
[PubMed]. TB_04_2025.

11. Isoniazid-dihydropyrimidinone Molecular Hybrids: Design, Synthesis, Antitubercular Activity, and Cytotoxicity Investigations with Computational Validation. Kumar, G., P. Seboletswe, S. Mishra, N. Manhas, S. Ghumran, N. Kerru, F. Roquet-Banères, M. Foubert, L. Kremer, G. Bhargava, and P. Singh. ChemMedChem, 2025. e2400949. PMID[40067058].
[PubMed]. TB_04_2025.

12. Leurs-targeting Prodrug, Mrx-5, Expresses Anti-Mycobacterium abscessus Activity. Li, A., S. He, Y. Jia, J. Fan, S. Liu, X. Wang, Z. Zhang, and H. Chu. Clinical and Experimental Pharmacology and Physiology, 2025. 52(4): e70024. PMID[39929481].
[PubMed]. TB_04_2025.

13. Verapamil Modulates Activity of Antimicrobials against Rapidly Growing Mycobacteria. Machado do Nascimento, A.A., C.T. Palomo, R.B.L. Scodro, K.R. Caleffi-Ferracioli, V.L.D. Siqueira, J.E. Meneguello, and R.F. Cardoso. Microbial Drug Resistance, 2025. 31(5): p. 162-167. PMID[40268501].
[PubMed]. TB_04_2025.

14. Novel Isoxazole Thiophene-containing Compounds Active against Mycobacterium tuberculosis. Martinez, G., K. Tolentino, P. Sukheja, J. Webb, C.W. McNamara, A.K. Chatterjee, and B. Yang. Bioorganic & Medicinal Chemistry Letters, 2025. 119: 130108. PMID[39863083].
[PubMed]. TB_04_2025.

15. Integrative Exploration of 2-phenylquinolin-4(1H)-one Tethered 1,2,3-triazole Derivatives: A Comprehensive In Vitro and In Silico Investigation Towards Novel Anti-tubercular Agents. Mehavi, R., W. Vinayak, P. Ashwini, P.K. Jaini, M.V. Nuli, B. Dvrn, and R. Kulkarni. Tuberculosis, 2025. 152: 102628. PMID[40086036].
[PubMed]. TB_04_2025.

16. The Potential of Medicinal Plants in Tuberculosis Treatment: Indigenous Plants Used by the Anak Dalam Tribe of Jambi, Indonesia. Muhaimin, M., U. Lestari, R. Hirzan, and A.Y. Chaerunisaa. South African Journal of Botany, 2025. 180: p. 688-709. ISI[001460476200001].
[WOS]. TB_04_2025.

17. Conjugate Delivery of D-cycloserine and Moxifloxacin Via Hydrolysable Cross Linkers -Mesoporous Silica Nanoparticles for Synergistic Effect on Multiple Drug Resistant on Tuberculosis. Nagashubha, B., L. Kumar, V.N.A. Dusthackeer, and Y.P. Reddy. Journal of Pharmaceutical Innovation, 2025. 20(2): 68. ISI[001459916800001].
[WOS]. TB_04_2025.

18. Antituberculosis Action of the Synthetic Peptide LKEKK. Navolotskaya, E.V., D.V. Zinchenko, A.A. Kolobov, Y.A. Zolotarev, and A.N. Murashev. Russian Journal of Bioorganic Chemistry, 2025. 51(2): p. 793-801. ISI[001460792600017].
[WOS]. TB_04_2025.

19. Repurposing of Apoptotic Inducer Drugs against Mycobacterium tuberculosis. Nyambo, K., V. Soko, K.I. Tapfuma, B. Motaung, F. Adu-Amankwaah, L. Julius, A. Klein, M. Keyster, L. Baatjies, L. Smith, K.K. Govender, M. Ngxande, A.G. Loxton, and V. Mavumengwana. Scientific Reports, 2025. 15(1): 7109. PMID[40016256]. PMCID[PMC11868625].
[PubMed]. TB_04_2025.

20. Mycobacterium tuberculosis Sulfate Ester Dioxygenase RV3406 is able to Inactivate the RCB18350 Compound. Recchia, D., G. Stelitano, A. Egorova, G. Batisti Biffignandi, K. Savková, R. Kafková, S. Huszár, A. Marino Cerrato, R.A. Slayden, J.E. Cummings, N. Whittel, A.A. Bauman, G.T. Robertson, L. Rank, F. Urbina, T.R. Lane, S. Ekins, O. Riabova, E. Kazakova, K. Mikušová, D. Sassera, G. Degiacomi, L.R. Chiarelli, V. Makarov, and M.R. Pasca. ACS Infectious Diseases, 2025. 11(4): p. 986-997. PMID[40111403]. PMCID[PMC11998004].
[PubMed]. TB_04_2025.

21. The Anti-mycobacterial Potential of Ibuprofen. Shah, P.T. and L. Xing. Tuberculosis, 2025. 152: 102638. PMID[40188657].
[PubMed]. TB_04_2025.

22. Synthesis and Structural Elucidation of Novel Quaternary Pyridinium Salt and Indolizine Derivatives as an Anti-tubercular Agent: In Silico and In Vitro Screening. Shende, S.U., P. Tiwari, S. Kidwai, R. Singh, and S. Chandrashekharappa. Journal of Molecular Structure, 2025. 1321: 139851. ISI[001453039100001].
[WOS]. TB_04_2025.

23. Comparative Evaluation of Five Β-lactamase Inhibitors in Combination with Β-lactams against Multidrug-resistant Mycobacterium tuberculosis In Vitro. Shi, J., D. Zheng, R. Su, X. Ma, Y. Zhu, S. Wang, W. Chang, and D. Sun. BMC Infectious Diseases, 2025. 25(1): 619. PMID[40295972]. PMCID[PMC12036291].
[PubMed]. TB_04_2025.

24. Determining the Effect of Natural Compounds on Mutations of Pyrazinamidase in Multidrug-resistant Tuberculosis: Illuminating the Dark Tunnel. Singh, R. and R. Purohit. Biochemical and Biophysical Research Communications, 2025. 756: 151575. PMID[40064092].
[PubMed]. TB_04_2025.

25. Exploring the Anti-tubercular Potential of 2-(1H-pyrazol-1-yl) pyrimidine: Design, Synthesis, Biological Evaluation and Molecular Docking Studies. Talamadla, M.K., A. Nandikolla, S. Shobha, P.P. Nayar, M.M.K. Kumar, M. Sankaranarayanan, and K. Sekhar. Chemistry & Biodiversity, 2025: e202500321. PMID[40070150].
[PubMed]. TB_04_2025.

26. Discovery of Novel Inhibitors for Malate Synthase of Mycobacterium tuberculosis from Natural Products. Wu, Z., Y. Wu, Y. Niu, Q. Hu, Q. Jiang, L. Liao, G. Qi, H. Lan, and X. Yang. Bioorganic & Medicinal Chemistry Letters, 2025. 123: 130217. PMID[40187434].
[PubMed]. TB_04_2025.

27. Florasulam is a Potent Inhibitor of Mycobacterium tuberculosis Acetohydroxyacid Synthase and Possesses In Vivo Antituberculosis Activity. Wun, S.J., L. Tan, T.G. Lonhienne, Y.S. Low, P. Josh, A. Kuo, M.T. Smith, Y. Gao, G.K. Pierens, L.W. Guddat, and N.P. West. ACS Infectious Diseases, 2025. PMID[40214257].
[PubMed]. TB_04_2025.

28. Structure-based Analysis of Semisynthetic Anti-Tb Rufomycin Analogues. Zhou, B., G. Shetye, L.L. Klein, N.M. Wolf, H. Lee, J.B. McAlpine, G. Harris, S.N. Chen, J.W. Suh, S.H. Cho, S.G. Franzblau, C. Abad-Zapatero, and G.F. Pauli. Journal of Natural Products, 2025. 88(4): p. 907-925. PMID[40126472]. PMCID[PMC12038834].
[PubMed]. TB_04_2025.

Patent Citations

This month, no relevant Mycobacterium patents were identified.